DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES

IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY
INFLUENCED BY INHIBITING THE ACTIVATION OF NF-kB

(Attorney Docket No. 016915-0244)

the specification of which (check one)

is attached hereto.

X was filed on January 17, 2000 as United States Application Number

or PCT International Application Number PCT/EP00/00323 and

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

was amended on _____ (if applicable).

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

S

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
199 07 895.5	Federal Republic of Germany	24 February 1999	YES	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT DAVID A. BLUMENTHAL BETH A. BURROUS Reg. No. 29,768

Reg. No. 26,257 Reg. No. 35,087

ALAN I. CANTOR	Reg. No.	28,163
WILLIAM T. ELLIS	Reg. No.	26,874
JOHN J. FELDHAUS	Reg. No.	28,822
MICHAEL D. KAMINSKI	Reg. No.	32,904
LYLE K. KIMMS	Reg. No.	34,079
KENNETH E. KROSIN	Reg. No.	25,735
JOHNNY A. KUMAR	Reg. No.	34,649
JACK LAHR	Reg. No.	19,621
GLENN LAW	Reg. No.	34,371
PETER G. MACK	Reg. No.	26,001
STEPHEN B. MAEBIUS	Reg. No.	35,264
BRIAN J. MC NAMARA	Reg. No.	32,789
SYBIL MELOY	. Reg. No.	22,749
RICHARD C. PEET	Reg. No.	35,792
GEORGE E. QUILLIN	Reg. No.	32,792
ANDREW E. RAWLINS	Reg. No.	34,702
BERNHARD D. SAXE	Reg. No.	28,665
CHARLES F. SCHILL	Reg. No.	27,590
RICHARD L. SCHWAAB	Reg. No.	25,479
MICHELE M. SIMKIN	Reg. No.	34,717
HAROLD C. WEGNER	Reg. No.	25,258

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Richard L. Schwaab FOLEY & LARDNER Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109

Telephone: (202) 672-5414 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	Gerd GEISSLINGER	
Residence	Bad Soden, Federal Republic of Germany	
Citizenship	Federal Republic of Germany	
Post Office Address	Drei-Linden-Strasse 31 D-65812 Bad Soden Federal Republic of Germany	
Inventor's signature		
Date	08/24/01	
Name of second inventor	Kay BRUNE	
Residence	Marloffstein, Federal Republic of Germany	
Citizenship	Federal Republic of Germany	
Post Office Address	Weiherackerweg 17 D-91080 Marloffstein Federal Republic of Germany	
Inventor's signature	Day Come	
Date _	8/20/101	

Applicant or Patentee: Gerd GEISSLINGER et al.

Serial or Patent No.: PCT/EP00/00323

Atty. Dkt. No. 016915/0244

Filed or Issued: January 17, 2000

For: USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO

TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID

DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING

THE ACTIVATION OF NF-KB

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.27) — SMALL BUSINESS CONCERN

				_
T	hereby	doctors	a that	Inm
Ł	HELEDA	ucciaid	i uiai.	шы

() the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: PAZ ARZNEIMITTEL-ENTWICKLUNGSGESELLSCHAFT MBH

ADDRESS OF CONCERN: In der Schildwacht 13, D-65933 Frankfurt am Main Federal Republic of Germany

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18 and reproduced in 37 CFR 1.27, for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled <u>USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF-κB by inventor(s) Gerd GEISSLINGER and Kay BRUNE described in</u>

()	the specification filed	l herewith		
(X)	application serial no.	PCT/EP00/00323,	filed January	17, 2000
()	patent no.	, issued		

Serial No.: PCT/EP00/00323

ATTORNEY DOCKET NO. 016915/0244

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.27(a)(1) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.27(a)(2) or a nonprofit organization under 37 CFR 1.27(a)(3). * NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities: (37 CFR 1.27)

NAME:
ADDRESS:
() INDIVIDUAL() SMALL BUSINESS CONCERN() NONPROFIT CORPORATION
NAME:
ADDRESS:
() INDIVIDUAL() SMALL BUSINESS CONCERN() NONPROFIT CORPORATION
I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate: (37 CFR 1.27.
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.
NAME OF PERSON SIGNING: TITLE OF PERSON OTHER THAN OWNER: ADDRESS OF PERSON SIGNING: D-65812 Zad Sodin, Kelkhe, mex Str. 69, German SIGNATURE: DATE: 29/08/01
·